AA PHASE III, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID¿) IN COMBINATION WITH MELPHALAN AND PREDNISONE VERSUS PLACEBO PLUS MELPHALAN AND PREDNISONE IN SUBJECTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE 65 YEARS OF AGE OR OLDER

AA PHASE III, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID¿) IN COMBINATION WITH MELPHALAN AND PREDNISONE VERSUS PLACEBO PLUS MELPHALAN AND PREDNISONE IN SUBJECTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE 65 YEARS OF AGE OR OLDER